- Home
- COCH vs ALLR Comparison
COCH vs ALLR Comparison
Compare COCH & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCH
- ALLR
- Stock Information
- Founded
- COCH 1995
- ALLR 2004
- Country
- COCH United States
- ALLR United States
- Employees
- COCH N/A
- ALLR N/A
- Industry
- COCH Blank Checks
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- COCH Finance
- ALLR Health Care
- Exchange
- COCH Nasdaq
- ALLR Nasdaq
- Market Cap
- COCH 20.9M
- ALLR 20.2M
- IPO Year
- COCH N/A
- ALLR N/A
- Fundamental
- Price
- COCH $0.71
- ALLR $1.16
- Analyst Decision
- COCH Strong Buy
- ALLR Strong Buy
- Analyst Count
- COCH 1
- ALLR 1
- Target Price
- COCH $9.50
- ALLR $9.25
- AVG Volume (30 Days)
- COCH 552.0K
- ALLR 285.7K
- Earning Date
- COCH 10-31-2025
- ALLR 11-14-2025
- Dividend Yield
- COCH N/A
- ALLR N/A
- EPS Growth
- COCH N/A
- ALLR N/A
- EPS
- COCH N/A
- ALLR N/A
- Revenue
- COCH $222,000.00
- ALLR N/A
- Revenue This Year
- COCH $3.66
- ALLR N/A
- Revenue Next Year
- COCH $31.19
- ALLR N/A
- P/E Ratio
- COCH N/A
- ALLR N/A
- Revenue Growth
- COCH N/A
- ALLR N/A
- 52 Week Low
- COCH $0.70
- ALLR $0.61
- 52 Week High
- COCH $2.32
- ALLR $2.35
- Technical
- Relative Strength Index (RSI)
- COCH 38.19
- ALLR 36.90
- Support Level
- COCH $0.70
- ALLR $1.34
- Resistance Level
- COCH $0.76
- ALLR $1.45
- Average True Range (ATR)
- COCH 0.06
- ALLR 0.10
- MACD
- COCH 0.00
- ALLR -0.03
- Stochastic Oscillator
- COCH 8.60
- ALLR 21.60
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.